As CIO, Andrew will lead our new Office of Innovation, driving cutting-edge research and development while ensuring continuous advancement and integration of new technologies. He will also oversee our Quality, Regulatory, and Clinical Studies teams.
Most recently, Andrew served as President and Chief Scientific Officer at Talis Biomedical, overseeing the menu expansion of the Talis One™ platform. Prior to that, he was the Chief Scientific Officer at Epigenomics AG, where he led the development of its next-generation blood-based colorectal cancer screening test. Earlier, as CEO of Millennium Health, a specialty CLIA laboratory, he successfully guided the organization through a strategic repositioning to drive future growth and success.
Andrew has also held senior leadership roles at molecular diagnostics companies, including AltheaDx, GenMark Diagnostics, Hologic, and Third Wave Technologies. He earned a BS in Biology from Penn State University and a PhD in Genetics from the University of Georgia.